Bay Colony Advisory Group Inc dba Bay Colony Advisors Makes New Investment in Becton, Dickinson and Company (NYSE:BDX)

Financial Advisors

Bay Colony Advisory Group Inc dba Bay Colony Advisors purchased new shares in Becton, Dickinson and Company (NYSE:BDX – Get Rating) in the fourth quarter, according to the latest Form 13F filed with the Securities and Exchange Commission . The company purchased 915 shares of a medical device supplier worth approximately $233,000.

Several other hedge funds and other institutional investors have also recently changed positions in the company. Radnor Capital Management LLC increased Dickinson’s stake in Becton by 3.9% in the fourth quarter. He owns 1,064 shares of the medical device supplier worth $270,000 after Radnor Capital Management LLC purchased another 40 shares during this period. Defined Wealth Management LLC increased its stake in Becton and Dickinson by 4.4% in the fourth quarter. Defined Wealth Management LLC now owns 950 shares of the medical device supplier worth $242,000 after purchasing an additional 40 shares during this period. Physicians Financial Services Inc. increased Dickinson’s Becton stake by 1.0% in the third quarter. Physicians Financial Services Inc. owns 4,517 shares of the medical device supplier worth $1,007,000 after purchasing an additional 46 shares during this period. Valmark Advisers Inc. increased his position in Becton, Dickinson stocks by 1.0% in the third quarter. Valmark Advisers Inc. now owns 4,800 shares of the medical device supplier worth $1,070,000 after purchasing an additional 46 shares during this period. Finally, Guardian Wealth Advisors LLC increased his Becton, Dickinson stake by 5.6% in the third quarter. Guardian Wealth Advisors LLC owns 893 shares of the medical device supplier worth $199,000 after acquiring an additional 47 shares during the previous quarter. 87.08% of the shares are owned by institutional investors and hedge funds.

Becton Dickinson and Price Performance

The NYSE BDX opened at $256.28 on Tuesday. The company has a 50-day moving average of $242.56 and a 200-day moving average of $241.30. The company has a quick ratio of 0.60, a current ratio of 1.07 and a debt to equity ratio of 0.56. The company has a market cap of $72.76 billion, a PE ratio of 48.35, a P/E ratio of 2.70, and a beta of 0.54. Becton, Dickinson and Company has a 12-month low of $215.90 and a 12-month high of $272.17.

Becton, Dickinson and (NYSE:BDX – Get Rating) last reported quarterly results on Thursday, February 2nd. The medical-device supplier posted its $2.98 earnings per share (EPS) for the quarter, $0.30 above consensus expectations of $2.68. Becton and Dickinson had a net profit margin of 8.47% and a return on equity of 13.52%. The company’s revenue for the quarter was $4.59 billion, compared with analyst estimates of $4.59 billion. Earnings for the same business in the year-ago quarter were $3.64. The company’s revenue fell 2.8% compared to the same quarter last year. Equity research analysts expect Becton, Dickinson & Co. to post earnings per share of 12.19 for the current year.

Becton, Dickinson Announce Dividends

The business recently announced a quarterly dividend, which was paid out on Friday, March 31st. Shareholders of record on Friday, March 10 were paid a dividend of $0.91. The ex-dividend date for this dividend was Thursday, March 9. This represents his $3.64 dividend and his 1.42% yield on an annual basis. Becton, Dickinson’s dividend payout ratio is 68.68%.

Wall Street analyst opinion

Several brokerage firms have commented on BDX. Bank of America upgraded shares of Becton, Dickinson from ‘neutral’ to ‘buy’ and raised its price target on the company from $250.00 to $290.00 in a research note on Tuesday, Jan. 3. Evercore ISI lowered price targets from $280.00 to his $275.00 for Becton, Dickinson, and set an “excellent” rating for the company in a report on Tuesday, April 4. Piper Sandler raised his price target on Becton and Dickinson from $245.00 to $260.00 in a research note on Thursday, February 2nd, giving the stock a “neutral” rating. Morgan Stanley raised Becton, Dickinson’s stock price target from her $290.00 to her $295.00, giving the company an “overweight” rating in its research notes on Friday, Feb. 3. Finally, began his coverage of Becton, Dickinson’s stocks and investigative reports on Thursday, March 16th. They set a “buy” rating for the company. Two equity research analysts rated the stock as a hold and seven rated the company’s stock as a buy. Based on MarketBeat data, the company’s current average rating is “moderate buy” with a consensus target price of $272.44.

insider bet

In another piece of news, EVP Richard Byrd sold 1,421 shares in a transaction that took place on Friday, February 3rd. The shares were sold at an average price of $248.60, giving him a total of $353,260.60. Following the closing of the sale, the Executive Vice President now owns 4,119 shares in the company, valued at approximately $1,023,983.40. The transaction was disclosed in legal filings with the SEC and is available at this link. The insider owns his 0.31% of the company’s shares.

Becton Dickinson and company profile

(get rating)

Becton, Dickinson & Co develops, manufactures and markets medical supplies, instruments, laboratory equipment and diagnostic products. It operates through the BD Medical, BD Life Sciences and BD Interventional segments. The BD Medical segment manufactures medical technologies and devices used to improve the delivery of healthcare.

Featured Stories

Want to know which other hedge funds hold BDX? Visit to get the latest Becton, Dickinson and Company (NYSE:BDX – Get Rating) 13F filings and insider trading.

Becton, Dickinson, and (NYSE:BDX) Quarterly Institutional Ownership

This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to

Becton, Dickinson, and before you want to hear this.

MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks that top analysts are quietly whispering to clients to buy now before the broader market catches on… and Becton, Dickinson, and The List. There was no

Becton, Dickinson, and currently have “moderate buy” ratings among analysts, although the top-rated analysts believe these five stocks are the better buys.

See 5 stocks here

20 shares to sell now

MarketBeat has released a list of 20 stocks selected by Wall Street analysts. dislikeWhile these companies may appear to have good fundamentals, top analysts smell serious corruption.any of these companies lurking About your portfolio? Enter your email address below to search.

Get This Free Report

20 stocks to sell now

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *